Latest News for: ligand pharmaceuticals
Edit
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (Form 8-K) (Ligand Pharmaceuticals Inc)
Public Technologies 14 Aug 2025
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering. JUPITER, Fla., August 11, 2025 (GLOBE NEWSWIRE) - Ligand Pharmaceuticals Incorporated (Nasdaq ... Ligand Pharmaceuticals Inc.
Edit
Statement of Changes in Beneficial Ownership (Form 4) (Ligand Pharmaceuticals Inc)
Public Technologies 12 Aug 2025
) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10 ... Washington, D.C ... OMB Number. 3235-0287 ... 0.5 ... 2 ... LIGAND PHARMACEUTICALS INC [LGND] 5 ... 6 ... Ligand Pharmaceuticals Inc.
Edit
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (Form 8-K) (Ligand Pharmaceuticals Inc)
Public Technologies 11 Aug 2025
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030. JUPITER, Fla., August 11, 2025 (GLOBE NEWSWIRE) - Ligand Pharmaceuticals Incorporated (Nasdaq ... Ligand Pharmaceuticals Inc.
Edit
Ligand Second Quarter 2025 Earnings Webcast (Ligand Pharmaceuticals Inc)
Public Technologies 08 Aug 2025
Strategic Pelthos merger completed and Zelsuvmi officiully luunchsd by Ligund purtnsr, Pelthos Ligand has ~50% equity interest in Pelthos and is entitled to a 13% royalty on Zelsuvmi sales ... Ligand Pharmaceuticals Inc.
Edit
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (Form 8-K) (Ligand Pharmaceuticals Inc)
Public Technologies 08 Aug 2025
) Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance ... JUPITER, Fla., August 7, 2025 - Ligand Pharmaceuticals Incorporated (Nasdaq ... About Ligand Pharmaceuticals ... Follow Ligand on X and LinkedIn ... Ligand Pharmaceuticals Inc.
Edit
Second Quarter 2025 Presentation (Ligand Pharmaceuticals Inc)
Public Technologies 08 Aug 2025
Strategic Pelthos merger completed and Zelsuvmi officiully luunchsd by Ligund purtnsr, Pelthos Ligand has ~50% equity interest in Pelthos and is entitled to a 13% royalty on Zelsuvmi sales ... Ligand' s Investment ... Ligand Pharmaceuticals Inc.
Edit
Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q) (Ligand Pharmaceuticals Inc)
Public Technologies 08 Aug 2025
References to "Ligand Pharmaceuticals Incorporated," "Ligand," the "Company," "we" or "our" include Ligand Pharmaceuticals Incorporated and our wholly-owned subsidiaries ... Ligand Pharmaceuticals Inc.
Edit
Notice of Proposed Sale of Securities (Form 144) (Ligand Pharmaceuticals Inc)
Public Technologies 01 Aug 2025
). The text version of this document is not available ... Ligand Pharmaceuticals Inc.
Edit
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (Form 8-K) (Ligand Pharmaceuticals Inc)
Public Technologies 02 Jul 2025
) Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics ... JUPITER, Fla., July 2, 2025 - Ligand Pharmaceuticals Incorporated (Nasdaq ... About Ligand Pharmaceuticals ... Follow Ligand on X and LinkedIn ... Ligand Pharmaceuticals Inc.
Edit
Proxy Results (Form 8-K) (Ligand Pharmaceuticals Inc)
Public Technologies 09 Jun 2025
The 2025 Annual Meeting of the Stockholders of Ligand Pharmaceuticals Incorporated (the "Company") was held on June 6, 2025 (the "Annual Meeting") ... Proposal 1 ... Votes For. Votes Withheld. Broker Non-Votes ... - ... Ligand Pharmaceuticals Inc.
- 1